Kidney transplantation is the definitive treatment for end-stage renal disease, offering substantial improvements in survival and quality of life. However, the lifelong immunosuppression required to maintain graft function predisposes recipients to a variety of posttransplant malignancies, which can cause morbidity and mortality. This report aimed to synthesize the current understanding of the epidemiology, risk factors, and clinical outcomes associated with posttransplant malignancies in kidney transplant recipients. Current understanding was drawn from review of international registries such as the Scientific Registry of Transplant Recipients and the Australia and New Zealand Dialysis and Transplant Registry, as well as landmark studies and clinical guidelines in the field of transplant oncology. The analysis showed that cancer incidence in kidney transplant recipients is 2 to 3 times higher than in the age-matched general population. Skin cancers, particularly nonmelanoma types, and posttransplant lymphoproliferative disorder are the most frequently observed malignancies. The pathogenesis is multifactorial, with intensity and duration of immunosuppression being the most important risk factor. Other critical factors include viral infections (eg, Epstein-Barr virus, human papillomavirus, BK virus), recipient age, and history of prior cancer. Some newer immunosuppressive agents, like mammalian target of rapamycin inhibitors, have shown promise in reducing the incidence of certain cancers, but their universal application is not supported by current evidence. Malignancy stands as a formidable challenge in the long-term management of kidney transplant recipients, second only to cardiovascular disease as a cause of death. A successful strategy to mitigate this risk requires a delicate balance between preventing graft rejection and minimizing the oncogenic potential of immunosuppressive therapy. Vigilant screening, individualized treatment regimens, and robust preventive measures are essential to improving outcomes and reducing the cancer burden in this vulnerable population.

Key words : Immunosuppression, Malignancy, Posttransplant lymphoproliferative disorder, Skin cancer

Introduction
For those of us caring for patients with end-stage renal disease, kidney transplant represents the most effective therapeutic modality, offering not just a longer life expectancy but a substantially better quality of life compared with long-term dialysis.¹ We struggle to secure these life-saving organs for our patients, and it is our responsibility to ensure the best possible long-term outcomes. Over the past few decades, modern advances in immunosuppressive therapy have been instrumental in preventing allograft rejection and extending the longevity of transplanted organs. However, this success is not without its costs. The requisite lifelong immunosuppression, although essential for graft survival, creates a state of impaired immune surveillance that substantially increases the recipient’s susceptibility to opportunistic infections and, most notably, malignancy.
As we have become more successful in preventing acute rejection, posttransplant malignancy (PTM) has emerged as one of the most formidable long-term challenges. After cardiovascular disease, cancer is now the second leading cause of death among transplant recipients most Western countries.² The overall incidence of cancer is estimated to be 2 to 3 times higher in solid-organ transplant recipients than in the general population, with certain malignancies showing a dramatically higher prevalence.³ This reality forces us as clinicians to navigate a difficult therapeutic landscape, constantly balancing the need to prevent graft rejection with the imperative to minimize the long-term risk of cancer. We must try to minimize, as much as we can, the side effects of transplantation. This report will explore the epidemiology, underlying risk factors, clinical presentation, and management strategies for malignancies that may occur in kidney transplant recipients, drawing on key registry data and clinical studies to provide a comprehensive overview of this critical issue.

Epidemiology
The burden of malignancy in the kidney transplant population is substantial, with registry data consistently demonstrating a significantly elevated risk compared with the general population. Analyses from major international registries, including the Scientific Registry of Transplant Recipients, the Australia and New Zealand Dialysis and Transplant Registry, and the Collaborative Transplant Study, confirmed this trend, although the precise risk varies depending on the organ type, geographic location, and the specific immunosuppressive protocols utilized.⁴
A landmark retrospective analysis of 884 pediatric kidney transplant recipients between 1963 and 2015 provided critical insights into the long-term incidence of PTM. The study reported a median patient survival of 33 years, during which 235 PTMs occurred in 138 individuals. The cumulative burden of malignancy increased over time, with 13% of patients developing a PTM by 20 years posttransplant, a rate that increased to 26% by 30 years posttransplant. The study showed that PTMs were the cause of death in 63.8% of the patients who developed cancer, highlighting its profound effect on long-term survival in this cohort.¹
The increase in cancer risk is not uniform across all types of malignancies. The most dramatic increases are seen in cancers with a known viral etiology. As shown in Table 1, nonmelanoma skin cancers and posttransplant lymphoproliferative disorder (PTLD) have an incidence ratio more than 5 times that of the general population. Other cancers with increased incidence include renal cell carcinoma, Kaposi sarcoma, thyroid cancer, and melanoma. In contrast, some of the most common cancers in the general population, such as breast, prostate, and ovarian cancer, do not show a significant increase in incidence after kidney transplant.⁴
Skin cancers are, by a significant margin, the most common malignancy, affecting a large proportion of recipients over their lifetime, particularly in regions with high sun exposure. Posttransplant lymphoproliferative disorder, strongly associated with Epstein-Barr virus (EBV) infection, is the second most common malignancy and represents a major cause of morbidity and mortality, especially in the early posttransplant period.²

Pathogenesis and Risk Factors
The development of PTM is a complex process driven by a confluence of factors, primarily centered on the state of iatrogenic immunosuppression. The risk of PTM can be broadly categorized into 3 main areas: patient-related factors, transplant-related factors, and medication-related factors.

Patient-related factors
Several intrinsic patient characteristics contribute to the overall risk. Advanced age at the time of transplant is a well-established risk factor, mirroring the age-related increase in cancer incidence in the general population. A previous history of cancer is also a significant predictor of PTM, with the risk of recurrence or the risk of a new primary malignancy being elevated. Sun exposure, particularly in fair-skinned individuals, is a major contributor to the high incidence of nonmelanoma skin cancers. Furthermore, the duration of dialysis prior to transplant has been associated with an increased risk of certain cancers, possibly due to chronic inflammation and uremia-induced immune dysfunction.
Viral infections play a pivotal role in the pathogenesis of many PTMs. The immunosuppressed state allows for the reactivation of latent viruses or the unchecked proliferation of new infections, some of which have direct oncogenic properties. Key viral pathogens include EBV, which is the primary driver of PTLD, particularly in EBV-seronegative recipients who receive an organ from an EBV-seropositive donor. Other key pathogens include human papillomavirus (associated with anogenital cancers and a subset of head and neck cancers), human herpesvirus-8 (the causative agent of Kaposi sarcoma), and BK virus (a polyomavirus linked to the development of urothelial carcinoma).

Transplant-related factors
Aspects of transplant can also influence cancer risk. Although rare, direct transmission of malignancy from the donor organ is a potential, although infrequent, cause of PTM, with an estimated incidence of less than 0.03%. The type of donor also appears to play a role, with some studies suggesting a lower risk of malignancy in recipients of living donor kidneys compared with deceased donor kidneys. Episodes of acute rejection, which often necessitate augmented immunosuppression, are also associated with a higher subsequent risk of malignancy.

Medication-related factors
The cornerstone of PTM risk is the immunosuppressive regimen. The overall burden of immunosuppression, both its intensity and duration, is the most critical determinant of cancer risk. Different classes of immunosuppressive drugs have been associated with varying levels of risk. These include calcineurin inhibitors, such as tacrolimus and cyclosporine, which are highly effective at preventing rejection but are associated with an increased risk of malignancy, likely through the inhibition of T-cell-mediated tumor surveillance. Other drugs include azathioprine, an older antimetabolite linked to the development of late nonmelanoma skin cancers and myelodysplastic syndromes, and mycophenolate mofetil, which appears to have a more neutral or potentially protective effect regarding malignancy risk compared with other agents. Finally, mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have antiproliferative properties and have shown a protective effect against certain cancers, notably Kaposi sarcoma and nonmelanoma skin cancers. However, their overall benefit remains a subject of debate, and meta-analyses have raised concerns about potential adverse effects, arguing against their universal use as a primary cancer prevention strategy.⁵

Clinical Presentation and Management
The clinical presentation of PTM is diverse and depends on the type and location of the malignancy. Nonmelanoma skin cancers are the most common presentation, often appearing as new or changing lesions on sun-exposed areas. Posttransplant lymphoproliferative disorder can present in a variety of ways, from isolated nodal disease to widespread systemic involvement, and frequently involves extranodal sites such as the transplanted kidney or the central nervous system. After skin cancers, genitourinary tract cancers are among the most frequently encountered malignancies in kidney transplant recipients.
The management of PTM is a multidisciplinary endeavor that requires careful coordination between transplant physicians, oncologists, and surgeons. The foundational principle of treatment is the reduction of immunosuppression. This is a critical first step, as it can allow for the restoration of some degree of immune surveillance against the tumor. However, this step must be done cautiously because of the risk of precipitating an acute rejection episode. In some cases, particularly with aggressive malignancies, a complete cessation of immunosuppression may be necessary, even if it means sacrificing the allograft and returning the patient to dialysis to save their life.
Beyond the modulation of immunosuppression, treatment follows standard oncologic principles, tailored to the specific cancer type and stage. For PTLD, the anti-CD20 monoclonal antibody rituximab has proven to be highly effective, particularly for B-cell lymphomas. For patients with skin cancers, a conversion to an mTOR inhibitor may be considered, given their demonstrated benefit in this context. Surgical excision, radiation therapy, and systemic chemotherapy are used as indicated, with careful consideration given to the patient’s overall health and the potential for drug interactions with the patient’s immunosuppressive regimen.

Case Illustration
The complexities of managing PTM are well illustrated by the case of a 72-year-old male patient with a long history of renal disease. He underwent his first kidney transplant in 1985; however, 10 years later, in 1995, he developed PTLD. This was managed by greatly reducing his immunosuppression, which led to the resolution of the lymphoma but ultimately resulted in the loss of the allograft and a return to dialysis. After the patient received a second transplant, he was maintained on a low-dose immunosuppressive regimen and had excellent graft function for many years. However, in 2009, he developed recurrent PTLD. This time, he was treated successfully with rituximab. Despite the successful management of his malignancy, his long-term course was complicated by other comorbidities, and he ultimately succumbed to cardiac-related complications in 2011. This case underscores the multifactorial nature of risk in long-term transplant care, where malignancy, cardiovascular disease, and the consequences of immunosuppression are all intertwined.

Conclusions
As emphasized in this report, malignancy represents a major and growing challenge in the long-term care of kidney transplant recipients, standing as a leading cause of death in this population. The risk of cancer is fundamentally driven by the necessary state of chronic immunosuppression. Although these drugs are the cornerstone of graft survival, they impair the body’s natural defenses against malignant cells. The interplay of immunosuppressive agents, viral infections, and patient-specific factors creates a complex risk profile that requires constant vigilance from the clinical team.
Although mTOR inhibitors have shown some promise in mitigating the risk of certain cancers, the hope for a universally applicable preventive strategy has not yet been realized, and a recent meta-analysis has even raised concerns about increased mortality with their use, arguing against routine adoption.⁴
Ultimately, there is no single solution, and the management of cancer risk in kidney transplant recipients requires a highly individualized approach. We must tailor the therapeutic strategy to the patient’s specific risk profile, considering their age, viral status, and history. A delicate and ongoing balance must be struck between providing sufficient immunosuppression to ensure graft survival and minimizing this therapy to reduce the long-term threat of malignancy. Vigilant screening for common PTMs, aggressive management of identified viral infections, and patient education on modifiable risk factors such as sun exposure are all critical components of a comprehensive care model. As our understanding of the complex interplay between the immune system, viral oncogenesis, and immunosuppressive agents continues to evolve, so too will our ability to improve the long and healthy survival of our transplant patients.

References:

1. Serrano OK, Bangdiwala AS, Vock DM, et al. Post-transplant malignancy after pediatric kidney transplantation: retrospective analysis of incidence and risk factors in 884 patients receiving transplants between 1963 and 2015 at the University of Minnesota. J Am Coll Surg. 2017;225(2):181-193. doi:10.1016/j.jamcollsurg.2017.04.012
   CrossRef - PubMed
2. Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J. 2018;11(3):315-329. doi:10.1093/ckj/sfx122
   CrossRef - PubMed
3. Au EH, Chapman JR, Teixeira-Pinto A, Craig JC, Wong G. Variations in risk of cancer and death from cancer according to kidney allograft function, graft loss, and return to dialysis. Transplantation. 2023;107(6):1359-1364. doi:10.1097/TP.0000000000004493
   CrossRef - PubMed
4. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81(9):1227-1233. doi:10.1097/01.tp.0000219817.18049.36
   CrossRef - PubMed
5. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4(8):1289-1295. doi:10.1111/j.1600-6143.2004.00515.x
   CrossRef - PubMed